- Enrolling by invitationPHASE2
Extension Study of Infigratinib in Children With Achondroplasia (ACH)
This study looks at a medicine called Infigratinib for children and teenagers aged 3-18 with achondroplasia, a type of dwarfism. It's an ongoing study to check the medicine's safety, how well it works, and its long-term effects on growth and quality of life.
For: AchondroplasiaUnited States · Argentina · Australia - Enrolling by invitationPHASE2
Open-Label, Long-Term, Extension Study of Infigratinib in Children With Hypochondroplasia
This study looks at a medicine called Infigratinib for children aged 3 to 18 with a condition called Hypochondroplasia. It's an ongoing study to understand its long-term safety and how well it helps kids who have already been part of a previous study.
For: HypochondroplasiaUnited States · Australia · Canada - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Infigratinib in Children 3 to <18 Years of Age with Achondroplasia: PROPEL 3
This study is testing a new medicine, Infigratinib, for children aged 3 to under 18 with achondroplasia. It aims to see if the medicine helps children grow taller and improves other health aspects, compared to a dummy pill.
For: AchondroplasiaSpain · France · Germany